Quentin M Anstee, Frcp

List of Publications by Citations

214 papers	18,496 citations	63 h-index	134 g-index
280 ext. papers	26,869 ext. citations	7.4 avg, IF	7.15 L-index

#	Paper	IF	Citations
214	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 11-20	24.2	1902
213	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 330-44	24.2	1022
212	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *Journal of Hepatology*, **2020**, 73, 202-209	13.4	764
211	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*, **2020**, 158, 1999-2014.e1	13.3	748
210	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-□and□□Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. *Gastroenterology*, **2016**, 150, 1147-1159.e5	13.3	629
209	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. *Journal of Hepatology*, **2015**, 62, 1148-55	13.4	626
208	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *Journal of Hepatology*, **2018**, 69, 896-904	13.4	550
207	Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. *International Journal of Experimental Pathology*, **2006**, 87, 1-16	2.8	527
206	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*, **2017**, 66, 1138-1153	19.2	508
205	From NASH to HCC: current concepts and future challenges. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 411-428	24.2	425
204	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet, The*, **2019**, 394, 2184-2196	40	425
203	Cellular senescence drives age-dependent hepatic steatosis. *Nature Communications*, **2017**, 8, 15691	17.4	408
202	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nature Communications*, **2014**, 5, 4309	17.4	362
201	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* , **2019**, 156, 1717-1730	13.3	356
200	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *Journal of Hepatology*, **2014**, 61, 75-81	13.4	310
199	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. *Annual Review of Pathology: Mechanisms of Disease*, **2016**, 11, 451-96	34	296
198	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *American Journal of Gastroenterology*, **2017**, 112, 740-751	0.7	273

197	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Gastroenterology*, **2020**, 158, 1611-1625.e12	13.3	234
196	The genetics of NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 645-55	24.2	232
195	Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. *Hepatology*, **2018**, 67, 1270-1283	11.2	225
194	Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. *Nature*, **2017**, 551, 340-345	50.4	224
193	Multigenerational epigenetic adaptation of the hepatic wound-healing response. *Nature Medicine*, **2012**, 18, 1369-77	50.5	217
192	Hypercoagulability in cirrhosis: causes and consequences. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 1713-23	15.4	182
191	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. *Frontline Gastroenterology*, **2014**, 5, 211-218	2.6	168
190	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature*, **2021**, 592, 450-456	50.4	164
189	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 362-373	18.8	151
188	S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. *Journal of Hepatology*, **2012**, 57, 1097-109	13.4	150
187	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. *Current Pharmaceutical Design*, **2013**, 19, 5219-38	3.3	148
186	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. *Journal of Hepatology*, **2020**, 73, 26-39	13.4	137
185	Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. *Gastroenterology*, **2016**, 150, 1728-1744.e7	13.3	133
184	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Scientific Reports*, **2017**, 7, 4492	4.9	131
183	Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. *Journal of Clinical Investigation*, **2015**, 125, 501-20	15.9	130
182	How big a problem is non-alcoholic fatty liver disease?. *BMJ, The*, **2011**, 343, d3897	5.9	129
181	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. *Gut*, **2017**, 66, 1321-1328	19.2	128
180	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *Journal of Hepatology*, **2012**, 56, 448-54	13.4	126

179	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. *Journal of Hepatology*, **2010**, 53, 542-50	13.4	122
178	Hypercoagulation and thrombophilia in liver disease. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 2-9	15.4	120
177	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 425-439	24.2	114
176	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. *Hepatology*, **2019**, 70, 1521-1530	11.2	113
175	Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. *Clinical Science*, **2015**, 129, 1097-105	6.5	113
174	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *Journal of Hepatology*, **2020**, 73, 505-515	13.4	113
173	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. *Seminars in Liver Disease*, **2015**, 35, 270-90	7.3	106
172	Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. *Clinical Epigenetics*, **2015**, 7, 25	7.7	104
171	Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2013**, 58, 757-62	13.4	99
170	Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 96-102.e3	6.9	92
169	Genetics of alcoholic and nonalcoholic fatty liver disease. *Seminars in Liver Disease*, **2011**, 31, 128-46	7.3	91
168	Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1336-43	15.4	89
167	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. *Hepatology*, **2018**, 67, 2001-2012	11.2	79
166	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. *BMJ Open*, **2021**, 11, e045922	3	78
165	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. *Journal of Hepatology*, **2020**, 72, 14-24	13.4	75
164	The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. *Journal of Hepatology*, **2018**, 68, 251-267	13.4	75
163	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. *Journal of Hepatology*, **2018**, 69, 878-885	13.4	75
162	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. *Contemporary Clinical Trials*, **2019**, 84, 105803	2.3	72

161	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. *Journal of Hepatology*, **2017**, 67, 128-136	13.4	70
160	Parenchymal extinction: coagulation and hepatic fibrogenesis. *Clinics in Liver Disease*, **2009**, 13, 117-126	4.6	67
159	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. *PLoS Medicine*, **2020**, 17, e1003100	11.6	66
158	Non-alcoholic fatty liver disease is associated with higher levels of measured sedentary behaviour and lower levels of physical activity than matched healthy controls. *Frontline Gastroenterology*, **2015**, 6, 44-51	2.6	65
157	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2020**, 73, 252-262	13.4	65
156	Nonalcoholic fatty liver disease: new treatments. *Current Opinion in Gastroenterology*, **2015**, 31, 175-83	3	65
155	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. *Journal of Hepatology*, **2019**, 71, 823-833	13.4	64
154	The role of hypercoagulability in liver fibrogenesis. *Clinics and Research in Hepatology and Gastroenterology*, **2011**, 35, 526-33	2.4	64
153	The International Normalized Ratio (INR) in the MELD score: problems and solutions. *American Journal of Transplantation*, **2010**, 10, 1349-53	8.7	59
152	TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?. *Gastroenterology*, **2015**, 148, 679-84	13.3	58
151	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2014**, 60, 1055-62	13.4	57
150	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. *European Journal of Gastroenterology and Hepatology*, **2013**, 25, 652-8	2.2	57
149	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 877-89	6.1	54
148	Quantifying hepatic steatosis - more than meets the eye. *Histopathology*, **2012**, 60, 971-81	7.3	54
147	Genetic modifiers of non-alcoholic fatty liver disease progression. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 1557-66	6.9	54
146	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 970-985	18.8	54
145	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1109-1116	6.1	53
144	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. *Diabetologia*, **2017**, 60, 1873-1882	10.3	51

143	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. *Science Translational Medicine*, **2020**, 12,	17.5	51
142	Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants. *BMC Biology*, **2018**, 16, 70	7.3	50
141	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. *New England Journal of Medicine*, **2021**, 385, 1547-1558	59.2	50
140	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology*, **2021**, 74, 775-782	13.4	50
139	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. *Contemporary Clinical Trials*, **2020**, 89, 105922	2.3	49
138	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. *JHEP Reports*, **2019**, 1, 188-198	10.3	46
137	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. *Contemporary Clinical Trials*, **2020**, 88, 105889	2.3	45
136	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. *Hepatology*, **2019**, 70, 1424-1436	11.2	44
135	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. *Cell Cycle*, **2014**, 13, 1489-94	4.7	44
134	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. *Hepatology*, **2019**, 70, 1841-1855	11.2	41
133	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2085-2092.e1	6.9	41
132	Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition. *Nature Communications*, **2013**, 4, 2816	17.4	37
131	Advancing the global public health agenda for NAFLD: a consensus statement. *Nature Reviews Gastroenterology and Hepatology*, **2021**,	24.2	37
130	The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. *Liver International*, **2015**, 35, 764-73	7.9	36
129	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 185-198	18.8	36
128	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. *PLoS ONE*, **2017**, 12, e0175717	3.7	35
127	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. *Journal of Hepatology*, **2019**, 70, e5	13.4	33
126	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2552-2560.e10	6.9	33

125	Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. *Clinical and Translational Gastroenterology*, **2014**, 5, e56	4.2	33
124	The PDGFRβ-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. *Oncogene*, **2017**, 36, 6605-6616	9.2	31
123	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. *PLoS ONE*, **2013**, 8, e61870	3.7	31
122	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1109-23	6.1	31
121	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. *Gastroenterology*, **2020**, 159, 534-548.e11	13.3	29
120	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. *Cancer Medicine*, **2017**, 6, 1930-1940	4.8	29
119	Genetics of Alcoholic Liver Disease. *Seminars in Liver Disease*, **2015**, 35, 361-74	7.3	29
118	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. *Clinical Science*, **2009**, 116, 403-13	6.5	29
117	Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. *Liver International*, **2021**, 41, 261-270	7.9	29
116	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemporary Clinical Trials*, **2020**, 98, 106175	2.3	28
115	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. *Hepatology*, **2020**, 71, 1953-1966	11.2	27
114	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. *Gut*, **2021**,	19.2	27
113	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 835-856	24.2	27
112	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. *Journal of Hepatology*, **2019**, 70, 1203-1213	13.4	26
111	Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. *Journal of Gastroenterology and Hepatology (Australia)*, **2008**, 23, 1403-9	4	25
110	Thrombin and factor Xa link the coagulation system with liver fibrosis. *BMC Gastroenterology*, **2018**, 18, 60	3	24
109	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. *Journal of Hepatology*, **2021**, 74, 20-30	13.4	24
108	Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. *Hepatology Research*, **2018**, 48, 69-77	5.1	22

107	Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. *Liver International*, **2011**, 31, 440-2	7.9	22
106	Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma. *Hepatology*, **2021**, 73, 1028-1044	11.2	22
105	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2021**, 75, 786-794	13.4	21
104	A missense mutation in the non-neural G-protein alpha-subunit isoforms modulates susceptibility to obesity. *International Journal of Obesity*, **2009**, 33, 507-18	5.5	20
103	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. *JHEP Reports*, **2020**, 2, 100142	14.3	20
102	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. *Hepatology*, **2021**, 74, 133-147	11.2	20
101	NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 506-507	24.2	19
100	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1364-1371.e3	6.9	19
99	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2021**, 75, 770-785	13.4	19
98	Investigating mildly abnormal serum aminotransferase values. *BMJ, The*, **2010**, 341, c4039	5.9	18
97	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1968-1971	6.9	17
96	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. *Nature Metabolism*, **2020**, 2, 514-531	14.6	17
95	The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2000**, 12, 1089-93	2.2	16
94	Defining comprehensive models of care for NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 717-729	24.2	16
93	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. *Frontline Gastroenterology*, **2017**, 8, 252-259	2.6	15
92	Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. *Frontline Gastroenterology*, **2013**, 4, 263-269	2.6	15
91	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. *Gastroenterology*, **2021**, 160, 1608-1619.e13	13.3	15
90	Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. *Hepatology*, **2021**, 74, 2452-2466	11.2	15

89	Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. *Clinical Medicine*, **2018**, 18, s54-s59	1.9	14
88	Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. *Postgraduate Medical Journal*, **2015**, 91, 92-101	2	14
87	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. *Clinical and Translational Gastroenterology*, **2020**, 11, e00231	4.2	14
86	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. *PLoS ONE*, **2020**, 15, e0238717	3.7	14
85	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. *Translational Behavioral Medicine*, **2020**, 10, 1016-1030	3.2	14
84	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. *Journal of Hepatology*, **2015**, 62, 982-3	13.4	13
83	An overview of the genetics, mechanisms and management of NAFLD and ALD. *Clinical Medicine*, **2015**, 15 Suppl 6, s77-82	1.9	13
82	The importance of fatty liver disease in clinical practice. *Proceedings of the Nutrition Society*, **2010**, 69, 518-27	2.9	13
81	European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. *JHEP Reports*, **2021**, 3, 100234	10.3	13
80	Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. *Hepatology*, **2010**, 51, 1859; author reply 1859-60	11.2	12
79	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. *Hepatology Communications*, **2020**, 4, 1637-1650	6	12
78	How to Diagnose Nonalcoholic Fatty Liver Disease. *Digestive Diseases*, **2016**, 34 Suppl 1, 19-26	3.2	11
77	NAFLD-Associated HCC: Progress and Opportunities. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 223-239	3.3	11
76	Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. *JHEP Reports*, **2020**, 2, 100099	10.3	10
75	Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. *Lasers in Surgery and Medicine*, **2011**, 43, 392-400	3.6	10
74	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. *Contemporary Clinical Trials*, **2018**, 75, 67-71	2.3	10
73	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. *Patient*, **2021**, 14, 533-543	3.7	9
72	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	8

71	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. *Postgraduate Medical Journal*, **2014**, 90, 254-66	2	7
70	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. *Journal of Hepatology*, **2017**, 66, S593	13.4	7
69	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. *Aging*, **2016**, 9, 26-40	5.6	7
68	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. *Hepatology*, **2021**,	11.2	7
67	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. *Journal of Hepatology*, **2021**,	13.4	7
66	Fatty Liver Disease **2018**, 308-371		6
65	The EPoS staging system is a reproducible 7-tierfibrosis score for NAFLD adapted both to glass slides and digitized images (e-slides). *Journal of Hepatology*, **2018**, 68, S553	13.4	6
64	1275 CARRIAGE OF PNPLA3 I148M IS ASSOCIATED WITH AN INCREASED RISK OF NON-ALCOHOLIC FATTY LIVER DIESEASE ASSOCIATED HEPATOCELLULAR CARCINOMA. *Journal of Hepatology*, **2013**, 58, S516	13.4	6
63	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. *Journal of Hepatology*, **2013**, 58, S46	13.4	6
62	Vectorial function of major histocompatibility complex class II in a human intestinal cell line. *Immunology*, **1999**, 98, 16-26	7.8	6
61	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1596-1603.e3	6.9	5
60	Genetic variation in GABR1 and the risk for developing alcohol dependence. *Psychiatric Genetics*, **2017**, 27, 110-115	2.9	5
59	A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'?. *Journal of Hepatology*, **2012**, 56, 987-9	13.4	5
58	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. *Journal of Hepatology*, **2022**,	13.4	5
57	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. *Journal of Hepatology*, **2021**,	13.4	5
56	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. *Gastroenterology*, **2021**,	13.3	5
55	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. *American Journal of Gastroenterology*, **2020**, 115, 1289-1292	0.7	5
54	A Role in the Genetic Predisposition to NAFLD-HCC?. *Cancers*, **2021**, 13,	6.6	5

53	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, **2021**, 10,	5.1	5
52	OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH **2019**,		5
51	A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation		5
50	Foreword. Nonalcoholic Fatty Liver Disease. *Seminars in Liver Disease*, **2015**, 35, 203-6	7.3	4
49	Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required?. *Journal of Hepatology*, **2014**, 61, 965-6	13.4	4
48	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. *Journal of Hepatology*, **2021**,	13.4	4
47	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. *JHEP Reports*, **2022**, 4, 100409	10.3	4
46	A molecular signature for the metabolic syndrome by urine metabolomics. *Cardiovascular Diabetology*, **2021**, 20, 155	8.7	4
45	Key features of the environment promoting liver cancer in the absence of cirrhosis. *Scientific Reports*, **2021**, 11, 16727	4.9	4
44	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.. *Biomedicines*, **2021**, 9,	4.8	4
43	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. *Journal of Hepatology*, **2017**, 66, S110-S111	13.4	3
42	81 A ROLE FOR ANTICOAGULATION IN FIBROGENESIS: SUPPRESSION OF HUMAN HEPATIC STELLATE CELL CONTRACTILITY AND LIVER FIBROSIS IN VITRO AND VIVO. *Journal of Hepatology*, **2012**, 56, S35-S36	13.4	3
41	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.. *JHEP Reports*, **2022**, 4, 100411	10.3	3
40	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. *Science Translational Medicine*, **2021**, 13, eabe8939	17.5	3
39	Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
38	Central obesity and nonalcoholic fatty liver disease in people living with HIV: a case for targeted screening?. *HIV Medicine*, **2019**, 20, e1-e2	2.7	3
37	Embedding assessment of liver fibrosis into routine diabetic review in primary care. *JHEP Reports*, **2021**, 3, 100293	10.3	3
36	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. *Expert Review of Gastroenterology and Hepatology*, **2021**, 15, 1253-1266	4.2	3

35	Exploring the patient perceived impact of non-alcoholic steatohepatitis. *Journal of Hepatology*, **2017**, 66, S422-S423	13.4	2
34	TM6SF2 as a genetic risk factor for fibrosis. *Hepatology*, **2015**, 62, 1321	11.2	2
33	Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.. *BMJ Open*, **2022**, 12, e049767	3	2
32	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. *BMJ Open Gastroenterology*, **2021**, 8,	3.9	2
31	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. *Hepatology*, **2022**,	11.2	2
30	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. *JHEP Reports*, **2022**, 4, 100477	10.3	2
29	Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.. *Hepatology Communications*, **2022**,	6	2
28	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. *Nature Genetics*,	36.3	2
27	Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". *Journal of Hepatology*, **2020**, 73, 221-222	13.4	1
26	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". *Journal of Hepatology*, **2014**, 60, 1330-1	13.4	1
25	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	1
24	2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design. *American Journal of Gastroenterology*, **2019**, 114, S1601-S1602	0.7	1
23	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease **2018**, 391-405.e3		1
22	Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways		1
21	Non-alcoholic Fatty Liver Disease (NAFLD) and Bariatric Surgery **2016**, 629-636		1
20	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
19	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. *Journal of Medical Internet Research*, **2021**, 23, e20491	7.6	1
18	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis **2018**, 68, 349		1

17	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.. *BMJ Open*, **2022**, 12, e056159	3	1
16	Impact of non-invasive biomarkers on hepatology practice: Past, present and future.. *Journal of Hepatology*, **2022**, 76, 1362-1378	13.4	1
15	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). *Canadian Liver Journal*, **2022**, 5, 61-90	0.3	0
14	The pathway to better primary care for chronic liver disease. *British Journal of General Practice*, **2021**, 71, 180-182	1.6	0
13	Reply. *Hepatology*, **2020**, 72, 786	11.2	
12	Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management **2013**, 157-170		
11	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. *American Journal of the Medical Sciences*, **2021**,	2.2	
10	New Challenges of the NAFLD and HIV Epidemics35-41		
9	Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease". *Journal of Hepatology*, **2020**, 73, 1582-1583	13.4	
8	Can genetic influence in non-alcoholic fatty liver disease be ignored? **2016**, 91-102		
7	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. *American Journal of Gastroenterology*, **2019**, 114, S546-S546	0.7	
6	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies **2020**, 17, e1003100		
5	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies **2020**, 17, e1003100		
4	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies **2020**, 17, e1003100		
3	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies **2020**, 17, e1003100		
2	Hepatitis B and Hepatitis C Co-Infection192-195		
1	Clinicians Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. *Journal of Clinical Medicine*, **2022**, 11, 2707	5.1	